Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study (PRP Randomized)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02672085
Recruitment Status : Unknown
Verified August 2017 by Adrien Schwitzguebel, La Tour Hospital.
Recruitment status was:  Recruiting
First Posted : February 3, 2016
Last Update Posted : August 22, 2017
Sponsor:
Collaborator:
Rive Droite SA
Information provided by (Responsible Party):
Adrien Schwitzguebel, La Tour Hospital

Brief Summary:

Background and Rationale:

Tedious PRP infiltrations are emerging treatments for tendinopathies and tendon tears. It has been showed effective in different parts of the body, but current evidences for rotator cuff PRP infiltration remains poor. Some studies that tested infiltrations on transfixing lesions showed no statistically significant effect of PRP on tendon healing. The investigators believe that this might be explained by a "flushing effect" of PRP into subacromial space or glenohumeral joint. Therefore, it was decided to focus this study on interstitial lesions, in which PRP is entrapped into the lesion for a long time.

Objective:

The purpose of this study is to evaluate whether intra-tear PRP infiltrations promotes tear repair better than needling procedures of torn tendon in participants with supraspinatus interstitial tears.

As secondary objective, we will study symptoms alleviation in same way. Primary outcome: Primary outcome: Supraspinatus tear size change from baseline will be compared between cases receiving two PRP injections and controls receiving torn tendon needling, 6 months after second injection.

Secondary outcomes: Single Assessment Numeric Evaluation score, Constant score, ASES score, Shoulder pain disability index, and Visual analogue scale changes from baseline will be compared between cases receiving two PRP injections and controls receiving torn tendon needling, 0,1,3, and 6 months after second injection.

Study design: This case-control study is randomized 1:1 between PRP (intervention group) and needling (Control group). It is a superiority trial that will include 84 patients suffering from interstitial supraspinatus tears. As adjuvant therapy, patients from each arm will beneficiate from standard physical therapy program. PRP and needling will be repeated 2 times, at one month interval. First injection will occur up to two months after recruitment. Clinical follow-up will occur from second injection to one year after second injection, with clinical parameters evaluation at 0,1,3, and 6 months after second injection, and control MRI 6 months after second injection.

Study Product / Intervention: Supraspinatus tendon needling with intralesional PRP injection. PRP will be extracted with Regenlab® extraction kit. No other medications used.

Control Intervention (if applicable): Supraspinatus tendon needling with intralesional saline water injection.

Number of Participants with Rationale: 84 patients will be needed (37 in each group). A 10% of dropout has been taken in consideration.

Study Duration: 24 months from recruitment of the first patient to the last follow-up visit. Scientific report will be written within the two months following recruitment of the last patient.

Study Schedule: First-Participant-In: 01.6.2015 Last-Participant-Out: 30.6.2017


Condition or disease Intervention/treatment Phase
Supraspinatis Interstitial Partial-thickness Tears Platelet-rich Plasma (PRP) Procedure: PRP infiltraiton Procedure: Needling Not Applicable

Detailed Description:

DETAILLED PLANNED STATISTICAL METHODS

Hypothesis

Null hypothesis: In patients with interstitial rotator cuff tear, there is no difference in term of tendon tear size percentage between baseline and 6 months after intervention.

Alternative hypothesis: In patients with interstitial rotator cuff tear, there is a difference in term of tendon of tendon tear size percentage between baseline and 6 months after intervention.

Determination of Sample Size

No previous data allows predicting the standard deviation of supraspinatus tear volume. In order to evaluate the standard deviation of tear size progression in percentage from baseline, investigators aimed to identify patients followed conservatively for interstitial supraspinatus tears, and in which two MRI has been performed at 3 to 9 months of interval. In this way, 25 patients were identified, and their tear sizes were measured. From this sample, an hypothetical standard deviation of 76% of the initial teas size was estimated. The investigators considered that potential PRP effect on tear size is clinically relevant if it allows a healing of 50% of the lesion size. Taking on consideration those points, 76 patients should be included to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) of 80%. The Type I error probability associated with this test of this null hypothesis is 0.05. Taking in consideration 10% of potential dropouts, it was planned to include 84 patients.

Following planned Analyses will be performed by Dr Adrien Schwitzguébel at the end of the study:

  • Baseline clinical parameters They will be compared between the two groups with adapted statistic tests (Chi-squared, Wilcoxon, or T test).
  • Primary outcome Supraspinatus tear size percentage difference between baseline and 6 months post intervention will be compared between the two groups with Student test.
  • Secondary outcome Clinical scores (Constant, ASES, SPADI, SANE, and VAS) differences between baseline and different time points will be compared between the two groups with Student test (or Wilcoxon test in case of non-parametric distribution). Even if those multiple analysis aims to evaluate clinical evolution of the two groups, no corrections will be applied on p values, but rather the aspect of a global tendency will be integrated in the discussion. In order to see whether small tears are more prone to beneficiate from treatment, correlation coefficient will be calculated between tear size percentage difference and initial tear size.
  • Handling of missing data and drop-outs In case of missing clinical parameters on interest for primary outcome calculation, patients will be excluded of the study. In case of missing clinical parameters on interest for secondary outcome calculation or baseline clinical parameters, analysis will be performed by removing patients with the missing value from corresponding analysis only.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study
Study Start Date : June 2015
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : December 2017

Arm Intervention/treatment
Experimental: PRP infiltration
Supraspinatus interstitial lesion needling and infiltration with PRP
Procedure: PRP infiltraiton
Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.

Active Comparator: Needling
Supraspinatus interstitial lesion needling and infiltration with NaCl
Procedure: Needling
Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.




Primary Outcome Measures :
  1. Lesion healing [ Time Frame: 6 months ]
    After second PRP injection, tendon healing will be assessed by comparison of baseline MRI and control MRI


Secondary Outcome Measures :
  1. Single Assessment Numeric Evaluation (SANE) score [ Time Frame: 0,1,3, and 6 months, and last follow-up (12 months or more) ]
    Changes from baseline will be compared between cases receiving two PRP injections and controls receiving tendon needling, 0,1,3, and 6 months after second injection.

  2. Pain Scores on the Visual Analogue Scale [ Time Frame: 0,1,3, 6 months, and last follow-up (12 months or more) ]
    Changes from baseline will be compared between cases receiving two PRP injections and controls receiving tendon needling, 0,1,3, and 6 months after second injection.

  3. Constant score [ Time Frame: 0,1,3, and 6 months ]
    Changes from baseline will be compared between cases receiving two PRP injections and controls receiving tendon needling, 0,1,3, and 6 months after second injection.

  4. ASES score [ Time Frame: 0,1,3, and 6 months ]
    Changes from baseline will be compared between cases receiving two PRP injections and controls receiving tendon needling, 0,1,3, and 6 months after second injection.

  5. Shoulder Pain Disability Index score [ Time Frame: 0,1,3, and 6 months ]
    Changes from baseline will be compared between cases receiving two PRP injections and controls receiving tendon needling, 0,1,3, and 6 months after second injection.

  6. Correlation between the initial tear size and the percentage of tear size evolution [ Time Frame: 6 months ]
    The tear size change will be evaluated between the 2 MRI, at the baseline and at the 6 months endpoints. This correlation will be separately evaluated in each study arm, and in the whole sample.

  7. Lesion healing between interstitial lesions that englobes or not the bone-tendon interface [ Time Frame: 6 months ]
    Tendon healing will be assessed by comparison of baseline MRI and control MRI

  8. Time limit in months from the first intervention to the last follow-up [ Time Frame: 12-36 months ]
    Will be measurerd in months

  9. Treatements at the end of the 6 months of PRP/Saline follow-up: Occurence of surgery [ Time Frame: between 6 months and the last follow-up ]
    The occurence of surgery will be reported in both groups: cases receiving two PRP injections and controls

  10. Treatements at the end of the 6 months of PRP/Saline follow-up: Occurence of corticoid infiltrations [ Time Frame: between 6 months and the last follow-up ]
    The number of infiltrations of the subacromial with corticosteroids bursa will be reported in both groups: cases receiving two PRP injections and controls

  11. Treatements at the end of the 6 months of PRP/Saline follow-up: Occurence of other infiltrations [ Time Frame: between 6 months and the last follow-up ]
    The nature number of infiltrations of the subacromial bursa with others substances (i.e. PRP, sclerosing agents, autologous blood, hyaluronic acid, ...) will be reported in both groups: cases receiving two PRP injections and controls

  12. Histological changes of tendon samples in case of surgery: tendon cellularity [ Time Frame: between 6 months and the last follow-up ]
    Cells count will be compared between cases receiving two PRP injections and controls

  13. Histological changes of tendon samples in case of surgery: vascularity [ Time Frame: between 6 months and the last follow-up ]
    Vascularity (CD34+ blood vessels count) will be compared between cases receiving two PRP injections and controls

  14. Histological changes of tendon samples in case of surgery: apoptosis [ Time Frame: between 6 months and the last follow-up ]
    Apoptosis (p53+ cells count) will be compared between cases receiving two PRP injections and controls



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed Consent as documented by signature (Appendix Informed Consent Form),
  • Symptomatic interstitial tear of the supraspinatus tendon,

Exclusion Criteria:

  • Tear of infraspinatus or subscapularis tendons (same shoulder)
  • Frozen shoulder (antepulsion deficit > 20%)
  • Corticosteroid shoulder infiltration in the 3 months prior the inclusion,
  • Patients suffering from symptomatic anaemia, or patients with severe cardiorespiratory insufficiency,
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Patients incapable of judgement or under tutelage,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02672085


Contacts
Layout table for location contacts
Contact: Schwitzguébel Adrien, MD adrien.schwitzgueel@latour.ch

Locations
Layout table for location information
Switzerland
La Tour Hospital Recruiting
Meyrin, Geneva, Switzerland, 1217
Contact: Adrien Schwitzguébel       adrien.schwitzguebel@latour.ch   
Sponsors and Collaborators
La Tour Hospital
Rive Droite SA
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Adrien Schwitzguebel, MD, La Tour Hospital
ClinicalTrials.gov Identifier: NCT02672085    
Other Study ID Numbers: RCPT PRP
First Posted: February 3, 2016    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No